ANIP Q4 2019 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q4 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$48M-16.0% YoY

Gross Profit

$30M62.9% margin

Operating Income

-$5M-9.7% margin

Net Income

-$5M-10.1% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

-6.6%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$3M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$457M

Total Liabilities

$244M

Stockholders' Equity

$213M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$57M	-16.0%
Gross Profit	$30M	$37M	-18.4%
Operating Income	-$5M	$11M	-140.8%
Net Income	-$5M	$5M	-189.9%

Revenue Segments

Performance Obligation From Prior Period

$17M86%

Sales Of Contract Manufactured Products

$3M14%

Geographic Segments

United States

$47M97%

Canada

$1M3%